
Please try another search
BofA Securities raised its price target on Biogen Inc (NASDAQ:BIIB) to $320.00 from $300.00 and maintained a Neutral rating following results from Eli Lilly and Company (NYSE:LLY) & Co. in early Alzheimer's disease, released on Wednesday.
According to BofA, the clear success of donanemab in Phase 3 will help to substantially diminish skepticism among physicians, payers, caregivers and patients, around the use of plaque removing antibodies. The firm believes the data reflects differences between the drugs and clinical trial populations that likely result in a split of an expanding market opportunity. But, overall, the firm thinks this data actually boosts the likelihood of a successful Leqembi launch.
Following the prolonged controversy surrounding Aduhelm, BofA believes that the success of lecanemab puts that story in the past. In the future, the firm expects that a second commercial effort in the space of Alzheimer, led by Eisai, will have a different outcome. The firm anticipates a quick approval from the FDA and a change at CMS on the reimbursement side opening up a much different commercial launch than it experienced for Aduhelm.
By Davit Kirakosyan
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.